KalVista Pharmaceuticals (KALV) Competitors $13.41 +0.45 (+3.47%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$13.41 0.00 (0.00%) As of 08/22/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. RXRX, CPRX, KNSA, OGN, ALVO, CNTA, IBRX, TARS, OCUL, and AGIOShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Recursion Pharmaceuticals (RXRX), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), ImmunityBio (IBRX), Tarsus Pharmaceuticals (TARS), Ocular Therapeutix (OCUL), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Its Competitors Recursion Pharmaceuticals Catalyst Pharmaceuticals Kiniksa Pharmaceuticals International Organon & Co. Alvotech Centessa Pharmaceuticals ImmunityBio Tarsus Pharmaceuticals Ocular Therapeutix Agios Pharmaceuticals Recursion Pharmaceuticals (NASDAQ:RXRX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation. Which has better earnings and valuation, RXRX or KALV? KalVista Pharmaceuticals has lower revenue, but higher earnings than Recursion Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.84M36.45-$463.66M-$1.78-2.78KalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-3.63 Do institutionals & insiders believe in RXRX or KALV? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor RXRX or KALV? In the previous week, Recursion Pharmaceuticals had 13 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 15 mentions for Recursion Pharmaceuticals and 2 mentions for KalVista Pharmaceuticals. KalVista Pharmaceuticals' average media sentiment score of 1.00 beat Recursion Pharmaceuticals' score of 0.79 indicating that KalVista Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive KalVista Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RXRX or KALV? Recursion Pharmaceuticals presently has a consensus target price of $7.00, indicating a potential upside of 41.70%. KalVista Pharmaceuticals has a consensus target price of $26.29, indicating a potential upside of 96.02%. Given KalVista Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Is RXRX or KALV more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Recursion Pharmaceuticals' return on equity of -76.09% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-1,004.91% -76.09% -54.29% KalVista Pharmaceuticals N/A -134.07%-82.65% Which has more volatility & risk, RXRX or KALV? Recursion Pharmaceuticals has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.05, indicating that its stock price is 95% less volatile than the S&P 500. SummaryRecursion Pharmaceuticals beats KalVista Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$675.06M$2.54B$5.82B$9.76BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-3.6322.7131.3826.05Price / SalesN/A752.44472.41122.40Price / CashN/A26.0925.7828.78Price / Book6.985.599.526.07Net Income-$183.44M$31.83M$3.26B$265.39M7 Day Performance4.11%1.89%2.14%2.00%1 Month Performance-14.04%1.62%3.22%0.46%1 Year Performance6.18%9.25%30.19%18.88% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.9019 of 5 stars$13.41+3.5%$26.29+96.0%+6.2%$675.06MN/A-3.63100Positive NewsRXRXRecursion Pharmaceuticals2.3551 of 5 stars$5.52-4.3%$7.00+26.8%-36.7%$2.51B$58.84M-3.10400News CoverageInsider TradeCPRXCatalyst Pharmaceuticals4.8925 of 5 stars$20.23flat$33.20+64.1%+3.7%$2.48B$491.73M12.2680News CoveragePositive NewsAnalyst DowngradeKNSAKiniksa Pharmaceuticals International2.6174 of 5 stars$33.72+1.0%$41.17+22.1%+23.3%$2.47B$423.24M843.21220News CoverageInsider TradeOGNOrganon & Co.4.7095 of 5 stars$9.27-1.8%$18.00+94.2%-57.9%$2.45B$6.40B3.454,000Positive NewsALVOAlvotech2.7494 of 5 stars$9.00+12.2%$14.00+55.6%-28.9%$2.42B$491.98M39.131,032News CoverageShort Interest ↓High Trading VolumeCNTACentessa Pharmaceuticals2.3618 of 5 stars$17.59-2.5%$28.10+59.7%+32.4%$2.42B$6.85M-9.83200IBRXImmunityBio2.5329 of 5 stars$2.43-4.7%$10.75+342.4%-45.6%$2.41B$14.74M-5.06590TARSTarsus Pharmaceuticals1.8866 of 5 stars$54.61+0.7%$66.67+22.1%+124.2%$2.29B$182.95M-23.4450News CoveragePositive NewsOCULOcular Therapeutix4.0761 of 5 stars$12.31-2.5%$17.20+39.7%+35.0%$2.20B$63.72M-9.62230Positive NewsAGIOAgios Pharmaceuticals4.3694 of 5 stars$37.45+1.2%$56.33+50.4%-16.1%$2.15B$36.50M3.40390Positive News Related Companies and Tools Related Companies RXRX Alternatives CPRX Alternatives KNSA Alternatives OGN Alternatives ALVO Alternatives CNTA Alternatives IBRX Alternatives TARS Alternatives OCUL Alternatives AGIO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access